Central Nervous System Complications of Cancer Therapy

Journal of Supportive Oncology

Volumn 10, Issue 4, 2012, Pages 133-141

  Rinne, Mikael L ^a   Lee, Eudocia Q ^a   Wen, Patrick Y ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ASPARAGINASE; BEVACIZUMAB; BUSULFAN; CAPECITABINE; CARMOFUR; CARMUSTINE; CETUXIMAB; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYTARABINE; DASATINIB; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; IFOSFAMIDE; IMATINIB; INTERFERON; METHOTREXATE; NELARABINE; NILOTINIB; PACLITAXEL; PENTOSTATIN; PROCARBAZINE; RETINOIC ACID; THIOTEPA; UNINDEXED DRUG;

ACUTE BRAIN DISEASE; ASEPTIC MENINGITIS; BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN PSEUDOTUMOR; BRAIN TUMOR; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLAR SYDROME; CEREBELLAR SYNDROME; CEREBELLUM DISEASE; CEREBRAL SINUS THROMBOSIS; COGNITIVE DEFECT; CONFUSION; CYTOREDUCTIVE SURGERY; DROWSINESS; DRUG MEGADOSE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FOCAL DYSTONIA; GLIOBLASTOMA; HALLUCINATION; HEADACHE; HUMAN; IRRITABILITY; LETHARGY; LEUKOENCEPHALOPATHY; MULTIMODALITY CANCER THERAPY; NAUSEA; PAPILLEDEMA; PARKINSONISM; PERSONALITY DISORDER; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROSTATE CANCER; PROTON THERAPY; RADIATION DOSE; RADIATION EXPOSURE; RADIATION HAZARD; RADIATION NECROSIS; RADIATION RESPONSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SIDE EFFECT; SKULL IRRADIATION; SOMNOLENCE; STEREOTACTIC RADIOSURGERY; STROKE; TRANSIENT ISCHEMIC ATTACK; VOMITING;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; CEREBRAL HEMORRHAGE; HEADACHE; HUMANS; LEUKOENCEPHALOPATHIES; RADIOTHERAPY; SEIZURES; STROKE;

EID: 84862764828     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.1016/j.suponc.2011.11.002     Document Type: Review

References (70)

1. Soussain C., Ricard D., Fike J.R., Mazeron J.J., Psimaras D., Delattre J.Y. CNS complications of radiotherapy and chemotherapy. Lancet 2009, 374(9701):1639-1651.
2. Cross N.E., Glantz M.J. Neurologic complications of radiation therapy. Neurol Clin 2003, 21(1):249-277.
3. Dietrich J., Monje M., Wefel J., Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008, 13(12):1285-1295.
4. Schulz-Ertner D., Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol 2007, 25(8):953-964.
5. Levin W.P., Kooy H., Loeffler J.S., DeLaney T.F. Proton beam therapy. Br J Cancer 2005, 93(8):849-854.
6. Young D.F., Posner J.B., Chu F., Nisce L. Rapid-course radiation therapy of cerebral metastases: results and complications. Cancer 1974, 34(4):1069-1076.
7. Wong C.S., Van der Kogel A.J. Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv 2004, 4(5):273-284.
8. Chin L.S., Lazio B.E., Biggins T., Amin P. Acute complications following gamma knife radiosurgery are rare. Surg Neurol 2000, 53(5):498-502.
9. Schulz-Ertner D., Haberer T., Scholz M., et al. Acute radiation-induced toxicity of heavy ion radiotherapy delivered with intensity modulated pencil beam scanning in patients with base of skull tumors. Radiother Oncol 2002, 64:189-195.
10. Faithfull S., Brada M. Somnolence syndrome in adults following cranial irradiation for primary brain tumours. Clin Oncol (R Coll Radiol) 1998, 10(4):250-254.
11. Vigliani M.C., Sichez N., Poisson M., Delattre J.Y. A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int J Radiat Oncol Biol Phys 1996, 35(3):527-533.
12. Brandsma D., Stalpers L., Taal W., Sminia P., van den Bent M.J. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008, 9(5):453-461.
13. Taal W., Brandsma D., de Bruin H.G., et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008, 113(2):405-410.
14. Chamberlain M.C., Glantz M.J., Chalmers L., Van Horn A., Sloan A.E. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007, 82(1):81-83.
15. Ruben J.D., Dally M., Bailey M., Smith R., McLean C.A., Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006, 65(2):499-508.
16. McGirt M.J., Bulsara K.R., Cummings T.J., et al. Prognostic value of magnetic resonance imaging-guided stereotactic biopsy in the evaluation of recurrent malignant astrocytoma compared with a lesion due to radiation effect. J Neurosurg 2003, 98(1):14-20.
17. Blonigen B.J., Steinmetz R.D., Levin L., Lamba M.A., Warnick R.E., Breneman J.C. Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2010, 77:996-1001.
18. Levin V.A., Bidaut L., Hou P., et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011, 79(5):1487-1495.
19. Douw L., Klein M., Fagel S.S., et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 2009, 8(9):810-818.
20. Mulhern R.K., Merchant T.E., Gajjar A., Reddick W.E., Kun L.E. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004, 5(7):399-408.
21. Monje M., Dietrich J. Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. Behav Brain Res 2010, 227(2):376-379.
22. Monje M.L., Toda H., Palmer T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003, 302(5651):1760-1765.
23. Shaw E.G., Rosdhal R., D'Agostino R.B., et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 2006, 24(9):1415-1420.
24. Meyers C.A., Weitzner M.A., Valentine A.D., Levin V.A. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998, 16(7):2522-2527.
25. Klein M., Heimans J.J., Aaronson N.K., et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002, 360(9343):1361-1368.
26. Dorresteijn L.D., Kappelle A.C., Boogerd W., et al. Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol 2002, 20(1):282-288.
27. Desai S.S., Paulino A.C., Mai W.Y., Teh B.S. Radiation-induced moyamoya syndrome. Int J Radiat Oncol Biol Phys 2006, 65(4):1222-1227.
28. Strenger V., Sovinz P., Lackner H., et al. Intracerebral cavernous hemangioma after cranial irradiation in childhood. Incidence and risk factors. Strahlenther Onkol 2008, 184(5):276-280.
29. Hijiya N., Hudson M.M., Lensing S., et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 2007, 297(11):1207-1215.
30. Dietrich J., Wen P.Y. Neurologic complications of chemotherapy. Cancer Neurology in Clinical Practice 2008, 287-326. Humana Press, Totowa, NJ. 2nd ed. D. Schiff, S. Kesari, P.Y. Wen (Eds.).
31. DeAngelis L.M., Posner J.B. Side effects of chemotherapy. Neurologic Complications of Cancer 2009, 447-510. Oxford University Press, New York. 2nd ed.
32. Wei G., Rafiyath S., Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 2010, 3:47.
33. Dillman R.O., Hendrix C.S. Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther 2003, 1(1):38-48.
34. Vassal G., Deroussent A., Hartmann O., et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990, 50(19):6203-6207.
35. Eberly A.L., Anderson G.D., Bubalo J.S., McCune J.S. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 2008, 28(12):1502-1510.
36. Hamidieh A.A., Hamedani R., Hadjibabaie M., Amini M., Sadrai S., Ghavamzadeh A. Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. Pediatr Hematol Oncol 2010, 27(7):529-533.
37. Jabbour E., O'Brien S., Kantarjian H., et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007, 109(8):3214-3218.
38. Jaeckle K.A., Batchelor T., O'Day S.J., et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 2002, 57(3):231-239.
39. Feinstein T.M., Gibson M.K., Argiris A. Cetuximab-induced aseptic meningitis. Ann Oncol 2009, 20:1609-1610.
40. Baker W.J., Royer G.L., Weiss R.B. Cytarabine and neurologic toxicity. J Clin Oncol 1991, 9(4):679-693.
41. Ajithkumar T., Parkinson C., Shamshad F., Murray P. Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol) 2007, 19(2):108-114.
42. Patel P.N. Methylene blue for management of ifosfamide-induced encephalopathy. Ann Pharmacother 2006, 40(2):299-303.
43. Pirzada N.A., Ali I.I., Dafer R.M. Fluorouracil-induced neurotoxicity. Ann Pharmacother 2000, 34(1):35-38.
44. Brashear A., Siemers E. Focal dystonia after chemotherapy: a case series. J Neurooncol 1997, 34(2):163-167.
45. Sarasombath P., Sumida K., Kaku D.A. Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia. Hawaii Med J 2002, 61(3):48. 57.
46. Crystal S.C., Leonidas J., Jakubowski A., Di Rocco A. Thalidomide induced acute worsening of Parkinson's disease. Movement Disord 2009, 24:1863-1864.
47. Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009, 6(8):465-477.
48. Gugliotta L., Mazzucconi M.G., Leone G., et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving l-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Eur J Haematol 1992, 49(2):63-66.
49. Hunault-Berger M., Chevallier P., Delain M., et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with l-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica 2008, 93(10):1488-1494.
50. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26):2666-2676.
51. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99(16):1232-1239.
52. Choueiri T.K., Schutz F.A., Je Y., Rosenberg J.E., Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010, 28(13):2280-2285.
53. Inaba H., Khan R.B., Laningham F.H., Crews K.R., Pui C.H., Daw N.C. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol 2008, 19(1):178-184.
54. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007, 96(12):1788-1795.
55. Besse B., Lasserre S.F., Compton P., Huang J., Augustus S., Rohr U.P. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010, 16(1):269-278.
56. Socinski M.A., Langer C.J., Huang J.E., et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009, 27(31):5255-5261.
57. Norden A.D., Young G.S., Setayesh K., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70(10):779-787.
58. Norden A.D., Drappatz J., Wen P.Y. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009, 5(11):610-620.
59. Nghiemphu P.L., Green R.M., Pope W.B., Lai A., Cloughesy T.F. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008, 10(3):355-360.
60. Norden A.D., Bartolomeo J., Tanaka S., et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol 2012, 106(1):121-125.
61. Taillibert S., Vincent L.A., Granger B., et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 2009, 72(18):1601-1606.
62. Wen P.Y., Yung W.K., Lamborn K.R., et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006, 12:4899-4907.
63. Marinella M.A., Markert R.J. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Intern Med J 2009, 39(12):826-834.
64. Glusker P., Recht L., Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006, 354:980-982.
65. Correa D.D., DeAngelis L.M., Shi W., Thaler H., Glass A., Abrey L.E. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004, 62(4):548-555.
66. Omuro A.M., Ben-Porat L.S., Panageas K.S., et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 2005, 62(10):1595-1600.
67. Hook C.C., Kimmel D.W., Kvols L.K., et al. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992, 31(3):262-267.
68. Videnovic A., Semenov I., Chua-Adajar R., et al. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. Neurology 2005, 65(11):1792-1794. 685.
69. Vardy J., Rourke S., Tannock I.F. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 2007, 25(17):2455-2463.
70. Gong X., Schwartz P.H., Linskey M.E., Bota D.A. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology 2011, 76(13):1126-1134.